in all species, and its activation IS the result of intracellular Ca'" levels (2, (11) (12) .
C-peptide C-peptide is formed in the process of transformation of proinsulin into insulin, and consists of 31 amino acids with a molecular weight of3000Da and a half-life of 13 minutes. It is stored in secretory granules, so as to be released subsequently by B cells, in equivalent amounts to those of insulin, in blood flow. It is a major factor in the formation of insulin, since it links chains A and B in such a way as to allow the proper looping in space, as well as the formation of disulphide bonds between the chains (13) (14) (15) .
When c-peptide moves away from proinsulin through the proteolytic process, the carboxyl end of the part of chain B of insulin remains exposed and free for the appropriate formation of an effective interaction with the insulin receptor (13) (14) (15) .
The role of c-peptide has not been clarified to date, while it has been considered to be inactive and acting only as a linking peptide in the formation of insulin (13) .
There are significant interactions between cpeptide and cell membrane, while there is direct evidence of a stereospecific binding of the peptide with its receptor, which is different from the receptor of insulin and other relevant hormones. Attachment of the c-peptide to the cellular surface takes place through a pair of G-type protein receptors, thus causing the stimulation of special intracellular processes (16) (17) (18) (19) (20) .
Published studies tried to confirm the orexigenic effect of Orexins when administered i.c.v. in rats and compared with a strong stimulant of food, neuropeptide Y (NPY) and two weaker stimulants: a) (MCH) melanin-concentrating hormone and b) galanin (21) .
There are researchers who have studied the changes in insulin and glucagon levels after IV injection of Orexin A in rats. Others have studied insulin concentrations after a subcutaneous injection of the neuropeptide, as well as in vitro into the pancreas of rats. Finally, other researchers have measured the changes in insulin and glucagon concentrations both in vivo and in vitro (22) .
As far as we know, no study has been published yet on the effect of i.c.v. administration of porcine Orexin A in fasting serum c-peptide, as described in the Methods section with two different doses (5 and 10 mg), with or without simultaneous intravenous glucose injection in pigs. The duration of the experiment was 30 minutes, and all blood samples were collected IS minutes prior to the beginning of each stage of the experiment, and immediately after the bolus, or at the beginning of continuous injection (0 minutes) and after 5, 15, and 30 minutes. The aim of this study is to investigate any possible connections between the effects of Orexin A on serum fasting concentration of c-peptide.
MATERIALS AND METHODS

Preparation ofthe experimental animals
The experimental protocol was applied in seven pigs and was carried out at two different times, with one-week interval. The injection of the neuropeptide, Orexin A (of porcine origin), was done into the lateral ventricle of the brain using a special catheter extracranially through a special valve placed at a previous time (1st time) before the injection (2 nd time). In order to place the catheter and the valve properly, it was considered necessary to perform a stereotactic examination of the skull by means of a CT scan.
Experimental protocol 1 st time Placement of the special device (valve) in the skull of the experimental animal was done under general anesthesia. The point of cranial trepanation is determined at 1/3 of the distance(0.5 to 1 em from midline) betweenthe midlineat the boundaries of the frontal bone (frontal part) and the occipital bone and the zygomaticprocessof the frontal bone ( Fig.2 ).
nd Time
The second time consists in the injection of the neuropeptide, Orexin A, into the lateral ventricle of the pig's brain. This is achieved after puncture (under local anesthesia), using a lumbar puncture needle, 21G in diameter, and with the device implanted at the 1st time as guide, under general anesthesia.
The administration of porcine Orexin A was done as follows: I) Rapid i.c.v. injection of the neuropeptide, in two doses of 5 and 10 mg, diluted in 0.5 ml of artificial cerebrospinal fluid (CSF), with one-hour interval.
2) The aforementioned method of administration was repeated, this time with simultaneous intravenous glucose administration. c-peptide plasma levels were measured in samples of 3 ml for each measure-ment.
The collections of blood samples were done as follows: 1) 15 minutes prior to the injection; 2) Immediately after rapid injection, and also after 5, 15, and 30 minutes. Following blood coagulation and centrifugation at 3000 rpm, the serum was collected in order to measure the levels of c-peptide. The serums were preserved at -70°C up to the date of the measurements.
For the determination ofc-peptide, a radioimmunoassay method with a standardized reagent of LINCO Research (1251 Radioimmunoassay Kit) was used.
Statistical analysis
The normal distribution of the sample's variables was tested through the application of the Kolmogorov-Smimov test (p>0.2). Several multivariate analyses of variance (MANOVAs) were carried out, in order to investigate the changes in c-peptide plasma levels (/lU/ml) after: a) rapid i.c.v. injection and b) rapid i.c.v. injection with simultaneous intravenous glucose administration, and with injection of: a) 0.5 ml of artificial CSF, b) 5 mg of porcine Orexin A, and c) 10 mg of porcine Orexin A.
Due to the existence of more than three pairwise comparisons (post hoc comparisons), Holm's Sequential Bonferroni Adjustment was applied to each comparison. Through this adjustment, the probability of Type-I error occurring in the study was reduced, by calculating a different a for every comparison applied by pairs. The level of significance of the study, a, was set to 0.05.
The changes in the plasma levels of the above variables were investigated after: 1) rapid i.e.v. injection, 2) rapid i.c.v. injection with simultaneous intravenous glucose administration through injection of: a) 0. 
RESULTS
Rapid i.c.v. injection of Orexin A in two doses of 5 and lOmg
Rapid i.c.v. injection of Orexin A in doses of 5 mg caused statistically significant changes in cpeptide plasma levels during the first 5 minutes of the experiment, resulting in an increase in c-peptide values from (l050.57±0.535 ng/ml) at time 0 to (l074.29±2.628 ng/ml) (p<O.OOI). C-peptide plasma levels continued to present a statistically significant increase until the end of the experiment, and reached a value of (l300.29±0.488 ng/ml) (p<O.OOI) ( Fig. 4 , Table I ).
Rapid i.c.v. injection of Orexin A in doses of 10 mg caused statistically significant increases in cpeptide values from time 0 (l050.29±0.488 ng/ml) up to the time-point of 5 minutes (l130.43±0.787 ng/ml) (p<O.OOI). A gradual increase in c-peptide levels was observed until the end of the experiment (p<O.OO I) ( Fig. 4 , Table I ).
Throughout the study, the plasma levels of c-peptide-and those of the other hormones-affected by the i.c.v. injection of aCSF are statistically much lower than the levels induced by the i.c.v. injection of Orexin A in doses of 5 and 10 mg (Tables I & II) . Rapid i.c.v. administration of Orexin A in doses of 5 mg with simultaneous glucose administration caused statistically significant changes in c-peptide plasma levels during the first 5 minutes of the experiment, resulting in an increase in its values from (l 050.29 ±0.488 ng/ml) at time 0 to (l320.43±0.787 ng/ml) (p<O.OOI). The plasma levels of c-peptide continued to present a statistically significant increase up to the end of the experiment reaching a value of (l890.71±0.951 ng/ml) (p<O.OOI) ( Fig. 5 , Table III ).
Rapid i.c.v. injection of Orexin A in doses of 10 mg, with simultaneous glucose administration, caused statistically significant increases in c-peptide values from time 0 (l050.23±0.488 ng/ml) until 5 minutes later (l320.43±O.787 ng/ml) (p<O.OOI). A gradual increase in c-peptide plasma levels was seen until the end of the experiment (p<O.OO I) ( Fig. 5 , Table III ).
The comparisons of c-peptide plasma levels at Fig. 4 . Mean values of c-peptide (ng/ml) after rapid i.e.v. injection of aCSF and Orexin A in doses of5 and 10 mg in seven pigs.
-15 o 5 15 30 Time (minutes) different times of the experiment (-15, 0 , 5, 15, and 30 minutes) following rapid injection of aCSF and Orexin A in doses of 5 and 10 mg, with simultaneous intravenous glucose admini stration, were statistically significant for 5 (p<O.OOI), IS (p<O.OOI) and 30 minutes (p<O.OO I) (Table IV) .
DISCUSSION
The neuropeptides of the hypothalamus, along with its neuronal circuits, are responsible for controlling feeding and energy homeostasis. Research on understanding the function of the hypothalamus and mapping the exact number of neuropeptides led to the discovery of Orexin A in 1998 (23) (24) (25) (26) (27) (28) .
Orexin A comes from neurons located in and round the lateral hypothalamic area, while showing close vicinity with glucose-sensitive neurons (29) (30) (31) (32) , and neurons producing and concentrating melatonin (33) . Both Orexin A and its corresponding receptor are also found outside the CNS. In particular, they have been found in the following: GI tract, pancreas (41), pituitary gland, adrenal glands (42), thyroid gland, kidneys, testicles (1-2, 31), and sympathetic neurons (ganglioneuroblastomas and neuroblastomas) (46) .
While Orexin A is produced by a small group of neurons located in and round the lateral hypothalamic area, their neuraxes present an impressive dispersion in different areas of the brain. The above anatomic finding also supports the involvement of Orexin A in many physiological functions, such as the effect on food or water intake, energy homeostasis, the circadian timing system, the endocrine end cardiovascular systems, the sleep-awakening and alertness cycle as well as on the sense of pain, thermogenesis, and temperature control of the organism (2) (3) (47) (48) (49) .
In particular, dense shunts of the orexigenic nerve fibres are observed in many parts of the brain, e.g.: olfactory bulb, cerebral cortex, amygdaloid nuclei, septum, hippocampus, basal ganglia, Broca's area, thalamus (anterior, medial and paraventricular nucleus), ventricular system, posterior hypothalamus, pituitary-pineal glands, dorsal nucleus of the vagus nerve, brainstem (central grey matter, nucleus of the cranial suture, locus ceruleus/LC end parabranchial nucleus), nucleus of the solitary tract, septum, midbrain, somesthetic nuclei, mammillary bodies, and spinal cord (2-3, 6, 10) .
The release of Orexin A seems to be largely controlled by leptin and the overall reserves of the organism in adipose tissue (1) (2) (50) (51) . The interactions among the three above factors, i.e., Orexin A, leptin, and adipose tissue, have not been Times (minutes) clarified (1-2, 52). One of the main reasons for this is the fact that the feeding phenomenon is extremely complicated and depends, both qualitatively and quantitatively, on the composition and the quantity of each particular meal, leading finally to the sensation of saturation (52).
The orexigenic system is considered to playa role of short-term mediator in food uptake control and, generally, in energy homeostasis. In response to an acute need for energy, especially when combined with low blood glucose values, or with the lack of food in general, the orexigenic system assumes a primary functional role (24, 52) .
Food uptake and energy homeostasis are affected by a large number of metabolic signals coming from -aCSF
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Orexin A tuue tissues, glands, organs, and systems of the organism and resulting in hypothalamus for a final evaluation and processing (52) . In humans, this phenomenon has even more complicated aspects, since other factors intrude as well, e.g., emotional status, socioeconomic background, genetic predisposition, and a large number of sensual signals related to the eating habits of the individual, which vary among different ages, countries, races, or even religions (52) .
The orexigenic neurons are in close vicinity to the glucose-sensitive neurons; as a result, the former are activated by a fall in glucose levels (29) . Besides, this is a deterministic confirmation, since glucose is the main metabolic fuel of the brain, and any fall or rise in glucose values induces the initiation and (2)-(3): p<O.OOI * S1: statistically insignificant; *statistically significant discontinuation of feeding, respectively (24, 29 ).
The orexigenic system is also detected in the enteric nervous system, since its neurons are located on the submucosal wall of the gastrointestinal tract and the corresponding ganglia (53) . The selection of c-peptide was made based on the criterion of its direct physiological correlation with the B cells of the pancreas. The latter constitute the origin of proinsulin, which, prior to the secretion, is split into insulin and c-peptide, in equimolecular quantities (13) . B cells of the pancreas in rats secreting insulin present immunoreactivity both to Orexin A and its corresponding receptor. Orexin A probably acts as a hormone and/or as a paracrine or autocrine transmitter of information from the pancreas to the hypothalamus and vice versa (3, 23) . The presence of Orexin A in human plasma supports the above point of view. Very little is known, however, on the regulatory role of Orexin A in the function of the pancreas (22) . Some studies have focused on the central administration of Orexin A in rats, and found that it causes an increase in the consumption of food and an increase in their metabolism. Meanwhile, the lack of food causes mRNA over-expression of the precursor substance of the neuropeptide, i.e., prepro-Orexin, thus suggesting the potential role of Orexin A as a mediator in the central feedback mechanism regulating feeding behaviour (1-2, 21,42) .
The aim ofour study is to investigate the potential effects of the neuropeptide Orexin-A on c-peptide plasma secretion and release in pigs with or without simultaneous intravenous glucose injection. By recording any changes in c-peptide plasma levels, at attempt is made to understand the principles of function and determine the degree of participation! effect of Orexin A in the function of the pancreas.
The i.c.v. injection ofOrex in A caused an increase in c-peptide values in a time-and dose-dependent way. The formation of c-peptide through the process of trans-formation of proinsulin into insulin and its storage in secretory granules, in order to be released subsequently together with insulin from the B cells of the pancreas, inevi-tably classifies it together with insulin (13, 16) . When injection was combined with simultaneous glucose administration, a proportionally larger stimulation was seen in mechanisms releasing c-peptide, The results of this study are probably attributed to the following physiological mechanism: the orexigenic neurons in hypothalamus are in close vicinity with the glucose-sensitive neurons, which, in turn, act on the main axis of Na+/K+ ATPase, where it is directly involved in the binding mechanism of c-peptide from its receptor, which is required for any activity (16) (17) . An i.c.v. injection of Orexin A probably follows the above course, while the simultaneous intravenous glucose administration provides an excessive supporting activity to the glucose-sensitive neurons of the hypothalamus (10, 24, 29) .
There are no experimental studies on pigs, or other experimental animals, in the international literature correlating an i.c.v. injection of porcine Orexin A in these doses of 5 and 10 mg, in a rapid way of administration, with the simultaneous administration of glucose and the subsequent collection of blood samples at 5 successive times for the determination of c-peptide plasma levels.
In conclusion, an i.c.v. injection of porcine Orexin A into the lateral ventricle of the pig's brain causes increases in plasma c-peptide concentrations, in a time-and dose-dependent way. When the i.c.v. injection of porcine Orexin A is accompanied by the simultaneous intravenous glucose injection, the levels of these increases in c-peptide plasma concentrations are even larger. These findings indicate the potential regulatory role of Orexin A in the function of the pancreas.
